This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Drugmaker Novo headed for EU approval for Catalent deal

By Natalie McNelis ( November 22, 2024, 15:31 GMT | Insight) -- Novo Holdings, the parent of Ozempic maker Novo Nordisk, appears on track to obtain unconditional EU approval for its $16.5 billion acquisition of US contract drugmaker Catalent, as the parties haven't been summoned to a "state of play" meeting, MLex has learned. The European Commission has until Dec. 6 to decide whether to clear the deal or send it for an in-depth investigation.Ozempic maker Novo Nordisk's parent company is on track to obtain unconditional EU approval for its $16.5 billion acquisition of US contract drugmaker Catalent, MLex has learned. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login